Weiterführende Literatur
IPCS. Global assessment of the state-of-the-science of endocrine disruptors. Genf, WHO. 2002
Bedogenetti D et al. An open, randomized, multicentre, phase 3 clinical trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. Eur Urol 2010;57:238-45
Braunstein GD. Gynecomastia. N Engl J Med 1993;328:490-5
Johnson RE et al. Gynecomastia: Pathophysiology, evaluation and management. Mayo Clinic Proc 2009;84:1010-5
Shrikrishna VA. Clinical features, presentation and hormonal parameters in patients with pubertal gynecomastia. J Family Med Prim Care 2021;10:648-51
Kanakis GA et al. EAA clinical practice guidelines - gynecomastia evaluation and management. Andrology 2019;7:778-93
Bembo SA et al. Gynecomastia: Its features, and when and how to treat it. Cleve Clin J Med 2004;71:511-7
Dickinson G. Gynecomastia. Am Fam Physician 2012;85:716-22
Lanciotti L et al. Up-to-date review about minipuberty and overview on hypothalamic-pituitary-gonadal axis. Activation in fetal and neonatal life. Front Endocrinol 2018;9:410
Becker M et al. Minipuberty: Why does it happen? Horm Res Paediatr 2020;93:76-84
Danksagung
Mein Dank gilt Frau Dr. Julia Saier für die kritische Durchsicht des Manuskripts.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Die Autorin erklärt, dass bei der Erstellung des Beitrags kein Interessenkonflikt vorlag.
Rights and permissions
About this article
Cite this article
Kuhnle-Krahl, U. In den allermeisten Fällen selbstlimitierend. Pädiatrie 34 (Suppl 1), 12–15 (2022). https://doi.org/10.1007/s15014-022-4068-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15014-022-4068-3